Oops! This Content is Members Only

Recent Content

• The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma
• Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
• Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
• Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
• Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
• Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
• Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission
• TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
• Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study
• Extracellular Vesicles in Multiple Myeloma-Cracking the Code to a Better Understanding of the Disease